Front-line Venetoclax and Obinutuzumab Combination Followed by Venetoclax or Venetoclax and Zanubrutinib Combination in Patients With Residual Disease: a Minimal Residual Disease (MRD) Tailored Treatment for Young Patients With High-risk CLL
Latest Information Update: 23 Nov 2023
At a glance
- Drugs Obinutuzumab (Primary) ; Venetoclax (Primary) ; Zanubrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms VIS
Most Recent Events
- 15 Nov 2023 Planned End Date changed from 1 Jan 2027 to 1 Jul 2027.
- 15 Nov 2023 Planned primary completion date changed from 1 Nov 2025 to 1 May 2026.
- 15 Nov 2023 Status changed from not yet recruiting to recruiting.